Pluriomics BV partners with Pivot Park Screening Centre to offer ultra High Throughput Screening for Cardiovascular drug discovery services

Leiden and Oss, The Netherlands, May 30th, 2017Pluriomics and Pivot Park Screening Centre today announced a collaboration to improve Pluriomics’ cardiovascular drug discovery service offerings and to expand Pivot Park Screening Centre’s knowledge about new and innovative assay technologies used to accelerate drug discoveries. Giving Pluriomics access to the Screening Centre’s ultra High Throughput Screening […]

READ MORE read more

Pluriomics BV collaborates with Multi Channel Systems to expand its Cardiovascular screening capabilities and its drug discovery services portfolio

Leiden, The Netherlands, 24th May, 2017Pluriomics and Multi Channel Systems (MCS) today announced a collaboration to work together on cardiac safety solutions and technology demonstration. This collaboration will give Pluriomics access to Multi Channel Systems’ new 1152 electrode 96 well MEA system which will expand Pluriomics’ cardiovascular drug screening services.  Pluriomics is a leading expert in human cardiovascular […]

READ MORE read more

News archive

Advances in Stem Cells and Regenerative Medicine

  Location: EMBL Heidelberg, Germany Date: May 23-26, 2017 Pluriomics will attend the Advances in Stem Cells and Regenerative Medicine conference at EMBL Heidelberg, Germany. This conference will provide a comprehensive overview of various aspects of stem cell biology. The cellular and molecular properties of normal tissue stem cells will be discussed, as well as […]

READ MORE read more

4th FDSS Application Workshop and 13th European Functional Drug Screening Symposium

  Pluriomics will attend the 4th FDSS Application Workshop and the 13th European Functional Drug Screening Symposium in Paris, France   Dates & Locations: June 7, 2017: The 4th FDSS Application WorkshopInstitute Necker Entfants Malades (INEM), Faculté de Médicine Paris Descartes, Bâtiment Leriche – Porte 14June 8, 2017: The 13th European Functional Drug Screening SymposiumSanofi Aventis […]

READ MORE read more

Events archive

About us

Pluriomics develops and commercializes fully functional, human iPSC-derived cardiomyocytes and provides high quality services for efficient and reliable safety pharmacology testing and cardiovascular drug efficacy screening.

Pluriomics, a leading expert in human cardiovascular stem cell technology, manufactures fully functional human iPSC derived cardiomyocytes (Pluricyte® Cardiomyocytes) using well-defined, serum-free medium that enhances the maturation and function of the cells. Pluriomics combines Pluricyte® Cardiomyocytes with innovative technologies to develop in-house cell-based assays with the objective to improve drug safety and efficacy screening.

Read more

Pluricyte® Cardiomyocyte Kit

Pluricyte® Cardiomyocyte Kit is developed and manufactured for use in drug discovery and development. The kit includes both Pluricyte® Cardiomyocytes and Pluricyte® Cardiomyocyte Medium (serum-free).

iView product information

Our solutions